Financing was provided by Ares Management Credit funds. Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. Tempus is a technology ...

Financing was provided by Ares Management Credit funds. Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. About Tempus Tempus is a ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics ...

Ambry, a 25-year-old genetics testing firm, is expected to generate over $300 million in revenue this year, with growth boosted by market share gains following Invitae’s bankruptcy.

On February 3 rd, the company announced that it had completed its acquisition of Ambry Genetics, a genetic testing company that strives to improve health by understanding the relationship between ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a ...

Highlights,Acquisition Deal Finalized:,Tempus AI acquired,Ambry Genetics,for,$600 million,in cash and stock.,Strategic Expansion:,The deal strengthens Tempus’ role in,AI-driven precision medicine and ...

In Q3 2024, Tempus announced its intent to acquire Ambry Genetics in a deal valued at 15x EBITDA at $600mm, $375mm of which through cash and the remaining $225mm in equity. Ambry will expand ...